Company profile: Harbin Medisan Pharmaceutical Co., Ltd. (abbreviated as Harbin Medisan) is a national high-and-new-tech enterprise that engaged in R&D, manufacturing and sales of chemical pharmaceutical finished dosage forms and APIs.

Founded in 1996, the company passed Chinese GMP certification of lyophilized powder injection, SVP and LVP in 2001 which make the company’s production capacity and economic benefit increased rapidly.

Since 2011, on the foundation of group operation for development, the company has officially established the Harbin Medisan Pharmaceutical Research Institute.

And also the company completed shareholding reform in 2013. It was successfully listed in SZSE on Sep. 22 2017.

Following the modern management philosophy and sincere operation, the company has won multiple honors including“AAA Grade Credit Enterprise” and “Top 100 Chinese Pharmaceutical R&D Enterprise in 2016”.

In the future, with the mission of “Medisan, we are here for you” and the culture of nourishing, charitable, humble, cooperative and sharing, the company will achieve its industrial chain integration and leap-forward expansion by capital operations through mergers, acquisitions and equality investment, strive to create a first-class pharmaceutical company that is driven by innovations, competitiveness and with core focus, lay a solid foundation for next hundred years to come.